Advertisement

Nail Unit Psoriasis

  • Dimitris Rigopoulos
  • Stamatis Gregoriou
Chapter

Abstract

Prevalence of nail psoriasis ranges from 7% to 56%, in psoriatic patients and significantly burdens quality of life. Nail psoriasis is associated with psoriatic arthritis and may be secondary to inflammation of the enthesis around the distal interphalangeal joint. Clinical features present due to inflammation of either the nail matrix or the nail bed and include pitting, leukonychia, red spots in the lunula, crumbling, onycholysis, splinter hemorrhages, subungual hyperkeratosis, and oil-drop salmon patches. Management of nail psoriasis should be individualized, and this depends on the number of nails affected, involvement of skin and/or joints, and co morbidities that might affect the choice of topical or systemic therapies.

Keywords

Prevalence Leukonychia Salmon patches Crumbling Onycholysis Splinter hemorrhages Subungual hyperkeratosis Enthesis Psoriatic arthritis Dermoscopy Severity indexes NAPSI Nail psoriasis in children Treatment Steroids Calcipotriol Tazarotene Acitretin Ciclosporin Methotrexate Ustekinumab Infliximab Etanercept Adalimumab 

Supplementary material

324020_4_En_6_MOESM1_ESM.pdf (33 kb)
Patient Handout (PDF 33 kb)

References

  1. 1.
    de Berker DAR, Baran R, Dawber RPR. The nail in dermatological diseases. In: Baran R, Dawber RPR, de Berker DAR, Haneke E, Tosti A, editors. Baran and Dawber’s diseases of the nails and their management. 3rd ed. Malden: Blackwell Science; 2001. p. 172–222.CrossRefGoogle Scholar
  2. 2.
    Richert B, Caucanas M. Epidemiology of nail psoriasis. In: Rigopoulos D, Tosti A, editors. Nail psoriasis From A to Z. Switzerland: Springer International Publishing; 2014. p. 1–11.Google Scholar
  3. 3.
    McGonagle D. Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol. 2009;23(Suppl 1):9–13.CrossRefPubMedGoogle Scholar
  4. 4.
    Radtke MA, Langenbruch AK, Schäfer I, Herberger K, Reich K, Augustin M. Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Relat Outcome Meas. 2011;2:1–6.PubMedGoogle Scholar
  5. 5.
    Augustin M, Reich K, Blome C, et al. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol. 2010;163:580–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Ortonne JP, Baran R, Corvest M, et al. Development and validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol. 2010;24:22–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Belyayeva E, Gregoriou S, Chalikias J, Kontochristopoulos G, Koumantaki E, Makris M, Koti I, Katoulis A, Katsambas A, Rigopoulos D. The impact of nail disorders on quality of life. Eur J Dermatol. 2013;23(3):366–71.PubMedGoogle Scholar
  8. 8.
    Rich P, Griffiths CE, Reich K, Nestle FO, Scher RK, Li S, Xu S, Hsu MC, Guzzo C, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2008;58(2):224–31.PubMedCrossRefGoogle Scholar
  9. 9.
    Baran R, Tosti A. Nails. In: Fitzpatrick TB, Freedberg IM, editors. Fitzpatrick’s dermatology in general medicine, vol. I. 6th ed. New York: McGraw-Hill, Medical Pub. Division; 2003.Google Scholar
  10. 10.
    van der Velden HM, Klaassen KM, van de Kerkhof PC, Pasch MC. Fingernail psoriasis reconsidered: a case-control study. J Am Acad Dermatol. 2013;69(2):245–52.PubMedCrossRefGoogle Scholar
  11. 11.
    Palmou N, Marzo-Ortega H, Ash Z, Goodfield M, Coates LC, Helliwell PS, McGonagle D. Linear pitting and splinter haemorrhages are more commonly seen in the nails of patients with established psoriasis in comparison to psoriatic arthritis. Dermatology. 2011;223(4):370–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Puri N, Mahajan BB. Nail changes in psoriasis – a profile. J Pak Assoc Dermatol. 2011;21(3):165–9.Google Scholar
  13. 13.
    Brazzelli V, Carugno A, Alborghetti A, Grasso V, Cananzi R, Fornara L, De Silvestri A, Borroni G. Prevalence, severity and clinical features of psoriasis in fingernails and toenails in adult patients: Italian experience. J Eur Acad Dermatol Venereol. 2012;26(11):1354–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg. 2003;7(4):317–21.PubMedCrossRefGoogle Scholar
  15. 15.
    Edwards F, de Berker D. Nail psoriasis: clinical presentation and best practice recommendations. Drugs. 2009;69(17):2351–61.PubMedCrossRefGoogle Scholar
  16. 16.
    Jadhav VM, Mahajan PM, Mhaske CB. Nail pitting and onycholysis. Indian J Dermatol Venereol Leprol. 2009;75(6):631–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Singh SK. Fingernail pitting in psoriasis and its relation with different variables. Indian J Dermatol. 2013;58(4):310–2.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Holzberg M. Common nail disorders. Dermatol Clin. 2006;24(3):349–54.PubMedCrossRefGoogle Scholar
  19. 19.
    Baran RL. A nail psoriasis severity index. Br J Dermatol. 2004;150:568–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Baran R, Dawber RPR. Baran and Dawber’s diseases of the nails and their management. 3rd ed. Malden: Blackwell Science; 2001.CrossRefGoogle Scholar
  21. 21.
    Wilkerson MG, Wilkin JK. Red lunulae revisited: a clinical and histopathologic examination. J Am Acad Dermatol. 1989;20(3):453–7.PubMedCrossRefGoogle Scholar
  22. 22.
    de Berker D. Erythronychia. Dermatol Ther. 2012;25(6):603–11.PubMedCrossRefGoogle Scholar
  23. 23.
    Lesher JL Jr, Peterson CM, Lane JE. An unusual case of factitious onychodystrophy. Pediatr Dermatol. 2004;21(3):239–41.PubMedCrossRefGoogle Scholar
  24. 24.
    Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1–27.PubMedCrossRefGoogle Scholar
  25. 25.
    Baran R, Dawber RPR, Haneke E, Tosti A, Bristow I. A text atlas of nails disorders: techniques in investigation and diagnosis. 3rd ed. London: Martin Dunitz; 2003.CrossRefGoogle Scholar
  26. 26.
    Zaias N. Psoriasis of the nail: a clinical-pathologic study. Arch Dermatol. 1969;99(5):567–79.PubMedCrossRefGoogle Scholar
  27. 27.
    Daniel CR 3rd, Iorizzo M, Piraccini BM, Tosti A. Grading simple chronic paronychia and onycholysis. Int J Dermatol. 2006;45(12):1447–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Tosti A, Piraccini B. Chapter 89: Biology of nails and nails disorders. In: Wolff K, editor. Fitzpatrick’s dermatology in general medicine. New York: McGraw-Hill; 2012.Google Scholar
  29. 29.
    Jackson RH. Splinter haemorrhages in the fingernails. Br Med J. 1963;2(5371):1485–6.PubMedGoogle Scholar
  30. 30.
    Bloom R, Tosti A. The clinical features of nail psoriasis. In: Rigopoulos D, Tosti A, editors. Nail psoriasis from A to Z. Switzerland: Springer International Publishing; 2014. p. 44–55.Google Scholar
  31. 31.
    Tosti A, Piraccini B. Dermatological diseases that affect the nail. In: Hordinsky MK, Sawaya M, Scher RK, editors. Atlas of hair and nails. Philadelphia: Saunders; 2000. p. xii. 252 p.Google Scholar
  32. 32.
    Kouskoukis CE, Scher RK, Ackerman AB. The “oil drop” sign of psoriatic nails. Am J Dermatopathol. 1983;5(3):259–62.PubMedCrossRefGoogle Scholar
  33. 33.
    Zaiac MN, Weiss E. Mohs micrographic surgery of the nail unit and squamous cell carcinoma. Dermatol Surg. 2001;27(3):246–51.PubMedGoogle Scholar
  34. 34.
    Zaias N. The nail in health and disease. 2nd ed. Norwalk: Appleton & Lange; 1990.Google Scholar
  35. 35.
    Tham SN, Lim JJ, Tay SH, Chiew YF, Chua TN, Tan E, Tan T. Clinical observations on nail changes in psoriasis. Ann Acad Med Singap. 1988;17:482–5.PubMedGoogle Scholar
  36. 36.
    Dogra A, Arora AK. Nail psoriasis: the journey so far. Indian J Dermatol. 2014;59(4):319–33.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Piraccini BM, Bruni F, Starace M. Dermoscopy of non-skin cancer nail disorders. Dermatol Ther. 2012;25(6):594–602.CrossRefPubMedGoogle Scholar
  38. 38.
    Gewirtzman AJ, Saurat JH, Braun RP. An evaluation of dermoscopy fluids and application techniques. Br J Dermatol. 2003;149(1):59–63.PubMedCrossRefGoogle Scholar
  39. 39.
    Tosti APB, Farias DC. Nail dermoscopy. In: Micali G, editor. Videodermatoscopy in clinical practice. London: Informa Healthcare; 2009.Google Scholar
  40. 40.
    Farias DC, Tosti A, Chiacchio ND, Hirata SH. Dermoscopy in nail psoriasis. An Bras Dermatol. 2010;85(1):101–3.PubMedCrossRefGoogle Scholar
  41. 41.
    Patel S, Tosti A. Dermoscopy of nail psoriasis. In: Rigopoulos D, Tosti A, editors. Nail psoriasis. From A to Z. Switzerland: Springer International publishing; 2014. p. 65–71.Google Scholar
  42. 42.
    Iorizzo M, Dahdah M, Vincenzi C, Tosti A. Videodermoscopy of the hyponychium in nail bed psoriasis. J Am Acad Dermatol. 2008;58(4):714–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Ohtsuka T, Yamakage A, Miyachi Y. Statistical definition of nail fold capillary pattern in patients with psoriasis. Int J Dermatol. 1994;33(11):779–82.PubMedCrossRefGoogle Scholar
  44. 44.
    Zaric D, Clemmensen OJ, Worm AM, Stahl D. Capillary microscopy of the nail fold in patients with psoriasis and psoriatic arthritis. Dermatologica. 1982;164(1):10–4.PubMedCrossRefGoogle Scholar
  45. 45.
    Bhushan M, Moore T, Herrick AL, Griffiths CE. Nail fold video capillaroscopy in psoriasis. Br J Dermatol. 2000;142(6):1171–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Lencastre A, Lamas A, Sá D, Tosti A. Onychoscopy. Clin Dermatol. 2013;31(5):587–93.PubMedCrossRefGoogle Scholar
  47. 47.
    Micali G, Lacarrubba F. Possible applications of videodermatoscopy beyond pigmented lesions. Int J Dermatol. 2003;42:430–3.PubMedCrossRefGoogle Scholar
  48. 48.
    Wortsman X, Soto R. Ultrasound imaging of psoriatic nails. In: Rigopoulos D, Tosti A, editors. Nail psoriasis. From A to Z. Switzerland: Springer International publishing; 2014. p. 58–63.Google Scholar
  49. 49.
    Gisondi P, Idolazzi L, Girolomoni G. Ultrasonography reveals nail thickening in patients with chronic placque psoriasis. Arch Dermatol Res. 2012;304(9):727–32.PubMedCrossRefGoogle Scholar
  50. 50.
    Aydin SZ, Castillo-Gallego C, Ash ZR, Abignano G, Marzo-Ortega H, Wittmann M, Del Galdo F, McGonagle D. Potential use of optical coherence tomography and high-frequency ultrasound for the assessment of nail disease in psoriasis and psoriatic arthritis. Dermatology. 2013;227(1):45–51.PubMedCrossRefGoogle Scholar
  51. 51.
    Aydin SZ, Ash Z, Del Galdo F, Marzo-Ortega H, Wakefield RJ, Emery P, McGonagle D. Optical coherence tomography: a new tool to assess nail disease in psoriasis? Dermatology. 2011;222(4):311–3.PubMedCrossRefGoogle Scholar
  52. 52.
    Ribeiro CF, Holler AP, Skake TL. Periungual capillascopy in psoriasis. Ana Bras Dermatol. 2012;87(4):550–3.CrossRefGoogle Scholar
  53. 53.
    Zaric D, Clemmerson Q, Worm A, Stahl D. Capillary microscopy of the nail fold in patients with psoriasis and psoriatic arthritis. Dermatologica. 1982;164:10–4.PubMedCrossRefGoogle Scholar
  54. 54.
    Salli L, Raimondi F, Pappalardo A. Periungual capillaroscopy in psoriatic arthritis. Clin Ter. 1999;150:409–12.PubMedGoogle Scholar
  55. 55.
    Tan ES, Chong WS, Tey HL. Nail psoriasis: a review. Am J Clin Dermatol. 2012;13:375–88.PubMedCrossRefGoogle Scholar
  56. 56.
    Jadhav VM, Mahajan PM, Mhaske CB. Nail pitting and onycholysis. Indian J Dermatol Venereol. 2009;75:631–3.l.CrossRefGoogle Scholar
  57. 57.
    Tosti A, Piraccani B. Dermatologic diseases. In: Scher RK, editor. Nails diagnosis, therapy and surgery. 3rd ed. Philadelphia: Saunders; 2005. p. 116.Google Scholar
  58. 58.
    Yin N, Tosti A. Differential diagnosis for nail psoriasis. In: Rigopoulos D, Tosti A, editors. Nail psoriasis from A to Z. Switzerland: Springer International Publishing; 2014. p. 86–95.Google Scholar
  59. 59.
    Yung A, Johnson P, Goodfield MJ. Isotretinoin-induced elkonyxis. Br J Dermatol. 2005;153:671–2.PubMedCrossRefGoogle Scholar
  60. 60.
    Greene RA, Scher RK. Nail changes associated with diabetes mellitus. J Am Acad Dermatol. 1987;16:1015–21.PubMedCrossRefGoogle Scholar
  61. 61.
    Baran R, Dawber RPR, Haneke E, Tosti A. Nail plate and soft tissue abnormalities. In: Baran R, Dawber RPR, Haneke E, Tosti A, Bristow I, Thomas L, et al., editors. A text atlas of nail disorders – techniques in investigation and diagnosis. London: Taylor & Francis; 2003.CrossRefGoogle Scholar
  62. 62.
    Tosti A, Piraccani BM. Nail disorders. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. Cambridge: Mosby Elsevier; 2012. cap. 70. p. 1019–36.Google Scholar
  63. 63.
    Tosti A, Daniel R, Piraccani B, Iorizzo M. Color atlas of nails. 1st ed. Berlin: Springer; 2009.Google Scholar
  64. 64.
    Daniel CR 3rd, Iorizzo M, Piraccini BM, Tosti A. Simple onycholysis. Cutis. 2011;87:226–8.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Dawber RP, Samman PD, Bottoms E. Fingernail growth in idiopathic and psoriatic onycholysis. Br J Dermatol. 1971;85:558–60.CrossRefPubMedGoogle Scholar
  66. 66.
    Natarajan V, Nath AK, Thappa DM, Singh R, Verma SK. Coexistence of onychomycosis in psoriatic nails: a descriptive study. Indian J Dermatol Venereol Leprol. 2010;76:723.PubMedGoogle Scholar
  67. 67.
    Sigurgeirsson B, Steingrimsson O. Risk factors associated with onychomycosis. J Eur Acad Dermatol Venereol. 2004;18:48–51.PubMedCrossRefGoogle Scholar
  68. 68.
    Kacar N, Ergin S, Ergin C, Erdogan BS, Kaleli I. The prevalence, aetiological agents and therapy of onychomycosis in patients with psoriasis: a prospective controlled trial. Clin Exp Dermatol. 2007;32:1–5.PubMedGoogle Scholar
  69. 69.
    Gupta AK, Lynde CW, Jain HC, Sibbald RG, Elewski BE, Daniel CR 3rd, Watteel GN, Summerbell RC. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Dermatol. 1997;136:786–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Klaassen KM, Dulak MG, van de Kerkhof PC, Pasch MC. The prevalence of onychomycosis in psoriatic patients: a systematic review. J Eur Acad Dermatol Venereol. 2014;28(5):533–41.PubMedCrossRefGoogle Scholar
  71. 71.
    Larsen GK, Haedersdal M, Svejgaard EL. The prevalence of onychomycosis in patients with psoriasis and other skin diseases. Acta Derm Venereol. 2003;83(3):206–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Dorschner RA, Lopez-Garcia B, Massie J, Kim C, Gallo RL. Innate immune defense of the nail unit by antimicrobial peptides. J Am Acad Dermatol. 2004;50(3):343–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Minisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C, et al. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol. 2003;14:333–7.CrossRefPubMedGoogle Scholar
  74. 74.
    Gregoriou S, Karagiorga T, Stratigos A, Volonakis K, Kontochristopoulos G, Rigopoulos D. Photo-onycholysis caused by olanzapine and aripiprazole. J Clin Psychopharmacol. 2008;28:219–20.PubMedCrossRefGoogle Scholar
  75. 75.
    Baran R, Juhlin L. Photoonycholysis. Photodermatol Photoimmunol Photomed. 2002;18:202–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Baran R, Juhlin L. Drug-induced photo-onycholysis. Three subtypes identified in a study of 15 cases. J Am Acad Dermatol. 1987;17:1012–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Gregoriou S, Argyriou G, Larios G, Rigopoulos D. Nail disorders and systemic disease: what the nails tell us. J Fam Pract. 2008;57:509–14.PubMedGoogle Scholar
  78. 78.
    Gregoriou S, Papafragkaki D, Rigopoulos D. Nails. In: Hall JC, Hall BJ, editors. Hall’s manual of skin as a marker of underlying disease: Shelton Connecticut USA: People’s medical publishing house; 2011. p. 207–26.Google Scholar
  79. 79.
    Scher RK, Daniel R. Nails: therapy, diagnosis, and surgery. Philadelphia: W.B. Sanders Company; 1990.Google Scholar
  80. 80.
    Blum M, Aviram A. Splinter hemorrhages in patients receiving regular hemodialysis. JAMA. 1978;239:47.PubMedCrossRefGoogle Scholar
  81. 81.
    Kelly MP, Kight MA, Castillo S. Trophic implications of altered body composition observed in or near the nails of hemodialysis patients. Adv Ren Replace Ther. 1998;M5:241–51.CrossRefGoogle Scholar
  82. 82.
    Sanders CV, Saenz RE, Lopez M. Splinter hemorrhages and onycholysis: unusual reactions associated with tetracycline hydrochloride therapy. South Med J. 1976;69:1090–2.PubMedCrossRefGoogle Scholar
  83. 83.
    Mortimer PS, Dawber RP. Trauma to the nail unit including occupational sports injuries. Dermatol Clin. 1985;3:415–20.PubMedCrossRefGoogle Scholar
  84. 84.
    Saladi RN, Persaud AN, Rudikoff D, Cohen SR. Idiopathic splinter hemorrhages. J Am Acad Dermatol. 2004;50:289–92.PubMedCrossRefGoogle Scholar
  85. 85.
    Kouskoukis CE, Scher RK, Ackerman AB. The “oil drop” sign of psoriatic nails. A clinical finding specific for psoriasis. Am J Dermatopathol. 1983;5:259–62.PubMedCrossRefGoogle Scholar
  86. 86.
    Haneke E. Nail psoriasis. In: Soung J, Koo B, editors. Psoriasis. Rijeka: Intech; 2011. 978-953-307-878.Google Scholar
  87. 87.
    Haneke E. Pathology. In: Rigopoulos D, Tosti A, editors. Nail psoriasis from A to Z. Switzerland: Springer International Publishing; 2014. p. 15–21.Google Scholar
  88. 88.
    Piraccini BM, Fanti PA, Morelli R, Tosti A. Hallopeau’s acrodermatitis continua of the nail: a clinical and pathological study of 20 patients. Acta Derm Venereol. 1994;74(1):65–7.PubMedGoogle Scholar
  89. 89.
    Rigopoulos D, Prevezas C. Severity evaluation indexes. In: Rigopoulos D, Tosti A, editors. Nail psoriasis from A to Z. Switzerland: Springer International Publishing; 2014. p. 1–11.Google Scholar
  90. 90.
    Pierard GE, Pierard-Franchmimont C. Dynamics of psoriatic trachyonychia during low-dose cyclosporine-A treatment: a pilot study on onychochronobiology using optical profilometry. Dermatology. 1996;192:116–9.CrossRefPubMedGoogle Scholar
  91. 91.
    Rich P, Scher R. Nail psoriasis severity-index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49:206–12.PubMedCrossRefGoogle Scholar
  92. 92.
    Rigopoulos D, Gregoriou S, Makris M, et al. Efficacy of Ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with Ustekinumab for cutaneous psoriasis: an open prospective unblinded study. Dermatology. 2011;223(4):325–9.PubMedCrossRefGoogle Scholar
  93. 93.
    Tosti A, Ricotti C, Romanelli P, et al. Evaluation of the efficacy of Acitretin therapy for nail psoriasis. Arch Dermatol. 2009;145(3):269–71.CrossRefPubMedGoogle Scholar
  94. 94.
    Bianchi L, Bergamin A, de Felice C, et al. Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol. 2005;52(4):736–7.PubMedCrossRefGoogle Scholar
  95. 95.
    Bardazzi F, Antonucci VA, Tengattini V, et al. A 36-week retrospective open trial comparing the efficacy of biological therapies in nail psoriasis. J Dtsch Dermatol Ges. 2013;11(11):1065–70.PubMedGoogle Scholar
  96. 96.
    Cassell SE, et al. The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol. 2007;34:123–9.PubMedGoogle Scholar
  97. 97.
    Aktan S, Ilknur T, Akin C, et al. Inter-observer reliability of the nail psoriasis severity index. Clin Exp Dermatol. 2007;32:141–4.PubMedCrossRefGoogle Scholar
  98. 98.
    Parrish CA, Sobera JO, Elewski BO. Modification of nail psoriasis severity index. J Am Acad Dermatol. 2005;53(4):745–6. author reply 746–7PubMedCrossRefGoogle Scholar
  99. 99.
    Augustin M, Blome C, Costanzo A, et al. Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. Br J Dermatol. 2014;170(3):591–8.PubMedCrossRefGoogle Scholar
  100. 100.
    Oran Y, Akkaya D. Treatment of nail psoriasis: common concepts and new trends. Dermatol Res Pract. 2013;23:1–13.CrossRefGoogle Scholar
  101. 101.
    Gregoriou S, Kalogeromitros D, Kosionis N, et al. Treatment options for nail psoriasis. Exp Rev Dermatol. 2008;3(3):339–44.CrossRefGoogle Scholar
  102. 102.
    Radtke A, Beikert F, Augustin M. Nail psoriasis-a treatment challenge. J Dtsch Dermatol Ges. 2013;103:203–19.Google Scholar
  103. 103.
    Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol. 2009;23(Suppl 1):15–21.PubMedCrossRefGoogle Scholar
  104. 104.
    Jaravuthisan M, Sasseville D, Vender R, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57:1–27.CrossRefGoogle Scholar
  105. 105.
    Dehesa L, Tosti A. Treatment of inflammatory nail disorders. Dermatol Ther. 2012;25:525–34.PubMedCrossRefGoogle Scholar
  106. 106.
    Cannavo SP, Guarneri F, Vaccaro M, et al. Treatment of psoriatic nails with topical cyclosporine: a prospective randomized, placebo-controlled study. Dermatology. 2003;206:153–6.PubMedCrossRefGoogle Scholar
  107. 107.
    De Berker D, Lawrence CM. A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol. 1998;138:90–5.PubMedCrossRefGoogle Scholar
  108. 108.
    De Berker D. Management of psoriatic nail disease. Semin Cutan Med Surg. 2009;28:39–43.PubMedCrossRefGoogle Scholar
  109. 109.
    Saleem K, Azim W. Treatment of nail psoriasis with a modified regimen of steroid injections. J Coll Physicians Surg Pak. 2008;18(2):78–81.PubMedGoogle Scholar
  110. 110.
    De Berker D. Management of nail psoriasis. Clin Exp Dermatol. 2000;25:357–62.PubMedCrossRefGoogle Scholar
  111. 111.
    Scher RK, Daniel CR. Nails: therapy, diagnosis, surgery. Philadelphia: W.B. Saunders Company; 2003.Google Scholar
  112. 112.
    Baran R, Tosti A. Treatment of nail psoriasis with a new corticoid – containing nail lacquer formulation. J Dermatol Treat. 1999;10:201–4.CrossRefGoogle Scholar
  113. 113.
    Sanchez Regana M, Martin Ezwuerra G, Millet U, et al. Treatment of nail psoriasis with 8% clobetasol nail lacquer: positive experience in 10 patients. J Eur Acad Dermatol Venereol. 2005;19:573–7.PubMedCrossRefGoogle Scholar
  114. 114.
    Nakamura R, Duque-Estrada B, Pizzaro Leverone A, et al. Comparison of nail lacquer clobetasol efficacy at 0, 05%, 1% and 8% in nail psoriasis treatment: prospective, controlled and randomized pilot study. An Bras Dermatol. 2012;87(2):203–11.PubMedCrossRefGoogle Scholar
  115. 115.
    van Le Q, Howard A. Dexamethasone iontophoresis for the treatment of nail psoriasis. Aust J Dermatol. 2013;54:115–9. Tosti A, Piraccini BM, Cameli N, et al. Calcipotriol ointment in nail psoriasis: a controlled, double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol. 1998;139:655–9.CrossRefGoogle Scholar
  116. 116.
    Tosti A, Piraccini BM, Cameli N, et al. Calcipotriol ointment in nail psoriasis: a controlled, double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol. 1998;139:655–9.PubMedCrossRefGoogle Scholar
  117. 117.
    Zakeri M, Valikhani M, Mortazavi H, et al. Topical calcipotriol therapy in nail psoriasis: a study of 24 cases. Dermatol Online J. 2005;11(3):5–9.PubMedGoogle Scholar
  118. 118.
    Rigopoulos D, Ioannides D, Prastitis N, et al. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Dermatol Venereol. 2002;82(2):140–3.CrossRefGoogle Scholar
  119. 119.
    Piraccini BM, Tosti A, Iorizzo M, et al. Pustular psoriasis of the nails: treatment and long-term follow-up of 46 patients. Br J Dermatol. 2001;144:1000–5.PubMedCrossRefGoogle Scholar
  120. 120.
    Balbas-Marquez M, Sanchez-Regana M, Millet-Umbert P. Tacalcitol ointment for the treatment of nail psoriasis. J Dermatol Treat. 2009;20(5):308–10.CrossRefGoogle Scholar
  121. 121.
    Kole L, Cantrell W, Elewski B. A randomized, double-blinded trial evaluating the efficacy and tolerability of vectical ointment (calcitriol 3 mcg/g ointment) when compared to betamethasone diproprionate ointment (64 mg/g) in patients with nail psoriasis. J Drugs Dermatol. 2014;13(8):912–5.PubMedGoogle Scholar
  122. 122.
    Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis. 2001;68:355–8.PubMedGoogle Scholar
  123. 123.
    Bianchi L, Soda R, Diluvio L, et al. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study. Br J Dermatol. 2003;149(1):207–9.PubMedCrossRefGoogle Scholar
  124. 124.
    Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with Tazarotene 0.1% gel vs clobetasol propionate 0.05% cream: a double-blind study. Acta Derm Venereol. 2007;87(2):167–8.PubMedCrossRefGoogle Scholar
  125. 125.
    Levancini-Fischer C, Sanchez-Regana M, Lambi F, et al. Nail psoriasis: treatment with tazarotene 0.1% hydrophilic ointment. Actas Dermosifiliogr. 2012;103(8):725–8.CrossRefGoogle Scholar
  126. 126.
    Fritz K. Successful local treatment of nail psoriasis with 5-fluorouracil. Z Hautarz. 1989;15(64):1083–8.Google Scholar
  127. 127.
    de Jong EM, Menke HE, van Praag MC, et al. Dystrophic psoriatic fingernails treated with 1% fluorouracil in a nail-penetration-enhancing vehicle. Dermatology. 1999;199:313–8.PubMedCrossRefGoogle Scholar
  128. 128.
    Yamamoto T, Katayana I, Nishioka K. Topical anthralin therapy for refractory nail psoriasis. J Dermatol. 1998;25(4):231–3.PubMedCrossRefGoogle Scholar
  129. 129.
    De Simone C, Maiorino A, Tassone F, et al. Tacrolimus 0,1% ointment in nail psoriasis: a randomized, controlled, open-label study. J Eur Acad Dermatol Venereol. 2013;27:1003–6.PubMedCrossRefGoogle Scholar
  130. 130.
    Hoffmann C, Plewig G. Photochemotherapie der nagelpsoriasis. Hautarzt. 1977;28:498–9.Google Scholar
  131. 131.
    Handfield-Jones SE, Boyle J, Harman RRM. Local PUVA treatment for nail psoriasis. Br J Dermatol. 1987;116(2):280–1.PubMedCrossRefGoogle Scholar
  132. 132.
    Stern DK, Creasey AA, Quigigie J, et al. UVA and UVB penetration of normal human cadaveric fingernail plate. Arch Dermatol. 2011;147(4):439–41.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Trieewittayapoon C, Sigvahamont P, Chanprapaph K, et al. The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: a randomized, doubleblind, intrapatient left-to-right study. J Am Acad Dermatol. 2012;66:807–12.CrossRefGoogle Scholar
  134. 134.
    Oram Y, Karincaoğlu Y, Koyuncu E, et al. Pulsed dye laser in the treatment of nail psoriasis. Dermatol Surg. 2010;36(3):377–81.PubMedCrossRefGoogle Scholar
  135. 135.
    Al-Mutairi N, Noor T, Al-Haddad. Single blinded left-to-right comparison study of excimer laser versus PDL for the treatment of nail psoriasis. Dermatol Ther. 2014;4:197–205.CrossRefGoogle Scholar
  136. 136.
    Tawifik AA. Novel treatment of nail psoriasis using the IPL: a 1-year follow-up study. Dermatol Surg. 2014;1:1–6.Google Scholar
  137. 137.
    Fernández-Guarino M, Harto A, Sánchez-Ronco M, et al. Pulsed dye laser vs photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study. J Eur Acad Dermatol Venereol. 2009;23(8):891–5.PubMedCrossRefGoogle Scholar
  138. 138.
    Rigopoulos D, Gregoriou S, Daniel CR, et al. Treatment of nail psoriasis with a two compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology. 2009;218:338–41.PubMedCrossRefGoogle Scholar
  139. 139.
    Sanchez Regana M, Marquez Balbas G, Millet Umbert P. Nail psoriasis: a combined treatment with 8% clobetasol nail laquer and tacalcitol ointment. J Eur Acad Dermatol Venereol. 2008;22:963–9.PubMedCrossRefGoogle Scholar
  140. 140.
    Huang YC, Chou CL, Chiang YY. Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: a single-blind, intrapatient left-to-right controlled study. Lasers Surg Med. 2013;45(2):102–7.PubMedCrossRefGoogle Scholar
  141. 141.
    Cantoresi F, Sorgi P, Arcese A, et al. Improvement of psoriatic onychodystrophy by a watersoluble nail lacquer. J Eur Acad Dermatol Venereol. 2009;23:832–4.PubMedCrossRefGoogle Scholar
  142. 142.
    Vlachou C, Berth-Jones J. Nail psoriasis improvement in a patient treated with fumaric acid esters. J Dermatol Treat. 2007;18:175–7.CrossRefGoogle Scholar
  143. 143.
    Lindelof B. Psoriasis of the nails treated with grenz rays: a double-blind bilateral trial. Acta Derm Venereol. 1989;69(1):80–2.PubMedGoogle Scholar
  144. 144.
    Yu RC, King CM. A double-blind study of superficial radiotherapy in psoriatic nail dystrophy. Acta Derm Venereol. 1992;72(2):134–6.PubMedGoogle Scholar
  145. 145.
    Kwang TY, Nee TS, Seng KT. A therapeutic study of nail psoriasis using electron beam. Acta Derm Venereol. 1995;75(1):90–2.PubMedGoogle Scholar
  146. 146.
    Ricceri F, Pescitelli L, Tripo L, et al. Treatment of severe nail psoriasis with acitretin: an impressive therapeutic result. Dermatol Ther. 2013;26(1):77–8.PubMedCrossRefGoogle Scholar
  147. 147.
    Mahrle G, Schultze HG, Farber L, et al. Low- dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nails and joint involvement. J Am Acad Dermatol. 1995;32:78–88.PubMedCrossRefGoogle Scholar
  148. 148.
    Sanchez-Regana M, Sola-Ortigosa J, Gibert-Alsina J, et al. Nail psoriasis: a retrospective study on the effectiveness of systemic treatment (classical and biological therapy). J Eur Acad Dermatol Venereol. 2011;25:57–586.CrossRefGoogle Scholar
  149. 149.
    Ojeda R, Sanchez-Regana M, Massana J, et al. Clinical experience with the use of cyclosporine A in psoriasis, results of a retrospective study. J Dermatol Treat. 2005;16:338–41.CrossRefGoogle Scholar
  150. 150.
    Feliciani C, Zampetti A, Forleo P, et al. Nail psoriasis: combined therapy with systemic cyclosporine and topical calcipotriol. J Cutan Med Surg. 2004;8:122–5.PubMedCrossRefGoogle Scholar
  151. 151.
    Syuto T, Abe M, Ishibuchi H, et al. Successful treatment of psoriatic nails with low-dose cyclosporine administration. Eur J Dermatol. 2007;17(3):248–9.PubMedGoogle Scholar
  152. 152.
    Gumusel M, Ozdemir M, Mevlitoglou I, et al. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol. 2011;25:1080–4.PubMedCrossRefGoogle Scholar
  153. 153.
    Lee JY. Severe 20-nail psoriasis successfully treated by low dose methotrexate. Dermatol Online. 2009;15(11):8–11.Google Scholar
  154. 154.
    Reich N, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate to- severe psoriasis: a phase III multicentre double-blind trial. Lancet. 2005;366:1367–74.PubMedCrossRefGoogle Scholar
  155. 155.
    Saricaoglu H, Oz A, Turan H. Nail psoriasis successfully treated with intralesional methotrexate: case report. Dermatology. 2011;222(1):5–7.PubMedCrossRefGoogle Scholar
  156. 156.
    Kyriakou A, Patsatsi A, Sotiriadis D. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study. J Dermatol Treat. 2013;24(3):162–8.CrossRefGoogle Scholar
  157. 157.
    Bardazzi F, Antonucci V, Odorici G, et al. A 36-week retrospective open trial comparing the efficacy of biological therapies in nail psoriasis. J Dtsch Dermatol Ges. 2013;11:1065–70.PubMedGoogle Scholar
  158. 158.
    Cassetty CT, Alexis AF, Shupack JL, et al. Alefacept in the treatment of psoriatic nail disease: a small case series. J Am Acad Dermatol. 2005;52(6):1101–2.PubMedCrossRefGoogle Scholar
  159. 159.
    Körver JE, Langewouters AM, Van De Kerkhof PC, et al. Therapeutic effects of a 12-week course of Alefacept on nail psoriasis. J Eur Acad Dermatol Venereol. 2006;20(10):1252–5.PubMedCrossRefGoogle Scholar
  160. 160.
    Parrish CA, Sobera JO, Robbins CM, et al. Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol. 2006;5(4):339–40.PubMedGoogle Scholar
  161. 161.
    Oram Y, Akkaya D. Treatment of nail psoriasis: common concepts and new trends. Dermatol Res Pract. 2013;2013:180496.CrossRefGoogle Scholar
  162. 162.
    Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2009;23(8):896–904.PubMedCrossRefGoogle Scholar
  163. 163.
    Ortonne JP, Paul C, Berardesca E, et al. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol. 2013;168(5):1080–7.PubMedCrossRefGoogle Scholar
  164. 164.
    Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis. 2010;69(2):394–9.PubMedCrossRefGoogle Scholar
  165. 165.
    Rigopoulos D, Gregoriou S, Lazaridou E, et al. Treatment of nail psoriasis with adalimumab. An open label, uncontrolled study. J Eur Acad Dermatol Venereol. 2010;24(5):530–4.PubMedCrossRefGoogle Scholar
  166. 166.
    Leonardi C, Langley RG, Papp K, et al. Adalimumab for the treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2011;147(4):429–36.PubMedCrossRefGoogle Scholar
  167. 167.
    Thaci D, Unnebrink K, Sundaram M, et al. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. JEADV. 2015;29:353–60.PubMedGoogle Scholar
  168. 168.
    Rich P, Griffiths C, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with Infliximab during 1 year. J Am Acad Dermatol. 2008;58:224–31.PubMedCrossRefGoogle Scholar
  169. 169.
    Rigopoulos D, Gregoriou S, Stratigos A, et al. Evaluation of the efficacy and safety of Infliximab on psoriatic nails: an unblinded, non-randomized, open-label study. Br J Dermatol. 2008;159(2):453–6.PubMedCrossRefGoogle Scholar
  170. 170.
    Torii H, Nakagawa H. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010;59:40–9.PubMedCrossRefGoogle Scholar
  171. 171.
    Fabroni C, Gori A, Troiano M, et al. Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients. J Eur Acad Dermatol Venereol. 2011;25:549–63.PubMedCrossRefGoogle Scholar
  172. 172.
    Rich P, Bourcier M, Sofen H, et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol. 2014;170:398–407.PubMedCrossRefGoogle Scholar
  173. 173.
    Rigopoulos D, Gregoriou S, Makris M, Ioannides D. Efficacy of Ustekinumab in nail psoriasis and improvement in nail associated QoL in a population treated with ustekinumab for cutaneous psoriasis. An open prospective unblinded study. Dermatology. 2011;223(4):325–9.PubMedCrossRefGoogle Scholar
  174. 174.
    Rallis E, Kintziglou S, Verros C. Ustekinumab for rapid treatment of nail psoriasis. Arch Dermatol. 2010;146(11):1315–6.PubMedCrossRefGoogle Scholar
  175. 175.
    Igarashi A, Kato T, Kato M, et al. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39:242–52.PubMedCrossRefGoogle Scholar
  176. 176.
    Vitiello M, Tosti A, Abuchar A, et al. Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients. Int J Dermatol. 2013;52:358–62.PubMedCrossRefGoogle Scholar
  177. 177.
    Patsatsi A, Kyriakou A, Sotiriadis D. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. J Dermatolog Treat. 2013;24:96–100.PubMedCrossRefGoogle Scholar
  178. 178.
    Paul C, Reich K, Gottlieb AB. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J EADV. 2014;28(12):1670–5.Google Scholar
  179. 179.
    Reich K, Sullivan J, Arenberger P, et al. Secukinumab is effective in subjects with moderate to severe plaque psoriasis with significant nail involvement: 16 weeks results from the TRANSFIGURE study. Poster 23rd World Congress of Dermatology, Vancouver, Canada. 2015.Google Scholar
  180. 180.
    Langley GR, Rich P, Menter A, et al. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. JEADV. 2015;29(9):1763–70.PubMedGoogle Scholar
  181. 181.
    Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). JAAD. 2016;74(1):134–14.PubMedCrossRefGoogle Scholar
  182. 182.
    Brazzelli V, Carugno A, Alborghetti A, Grasso V, Cananzi R, Fornara L, et al. Prevalence, severity and clinical features of psoriasis in fingernails and toenails in adult patients: Italian experience. J Eur Acad Dermatol Venereol. 2012;26(11):1354–9.PubMedCrossRefGoogle Scholar
  183. 183.
    Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61(2):233–9.PubMedPubMedCentralCrossRefGoogle Scholar
  184. 184.
    Tan AL, Grainger AJ, Tanner SF, Emery P, McGonagle D. A high-resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same? Arthritis Rheum. 2006;54(4):1328–33.PubMedCrossRefGoogle Scholar
  185. 185.
    Tan AL, Benjamin M, Toumi H, Grainger AJ, Tanner SF, Emery P, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis – a high-resolution MRI and histological study. Rheumatology (Oxford). 2007;46(2):253–6.CrossRefGoogle Scholar
  186. 186.
    Scarpa R, Soscia E, Peluso R, Atteno M, Manguso F, Del Puente A, et al. Nail and distal interphalangeal joint in psoriatic arthritis. J Rheumatol. 2006;33(7):1315–9.PubMedGoogle Scholar
  187. 187.
    Aydin SZ, Castillo-Gallego C, Ash ZR, Marzo-Ortega H, Emery P, Wakefield RJ, et al. Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy. Dermatology. 2012;225(3):231–5.PubMedCrossRefGoogle Scholar
  188. 188.
    Aydin SZ, Ash ZR, Tinazzi I, Castillo-Gallego C, Kwok C, Wilson C, et al. The link between enthesitis and arthritis in psoriatic arthritis: a switch to a vascular phenotype at insertions may play a role in arthritis development. Ann Rheum Dis. 2013;72(6):992–5.PubMedCrossRefGoogle Scholar
  189. 189.
    Shbeeb M, Uramoto KM, Gibson LE, O’Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol. 2000;27(5):1247–50.PubMedGoogle Scholar
  190. 190.
    Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol. 2003;4(7):441–7.PubMedCrossRefGoogle Scholar
  191. 191.
    Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537–41.PubMedCrossRefGoogle Scholar
  192. 192.
    Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA) – an analysis of 220 patients. Q J Med. 1987;62(238):127–41.PubMedGoogle Scholar
  193. 193.
    Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55–78.PubMedCrossRefGoogle Scholar
  194. 194.
    Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–73.PubMedCrossRefGoogle Scholar
  195. 195.
    Khraishi M, Chouela E, Bejar M, Landells I, Hewhook T, Rampakakis E, et al. High prevalence of psoriatic arthritis in a cohort of patients with psoriasis seen in a dermatology practice. J Cutan Med Surg. 2012;16(2):122–7.PubMedGoogle Scholar
  196. 196.
    Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72(5):736–40.PubMedCrossRefGoogle Scholar
  197. 197.
    Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009;27(3):469–74.PubMedGoogle Scholar
  198. 198.
    Gladman DD, Schentag CT, Tom BD, Chandran V, Brockbank J, Rosen C, et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis. 2009;68(4):497–501.PubMedCrossRefGoogle Scholar
  199. 199.
    Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE questionnaire: pilot- testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol. 2007;57(4):581–7.PubMedCrossRefGoogle Scholar
  200. 200.
    Alenius GM, Stenberg B, Stenlund H, Lundblad M, Dahlqvist SR. Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol. 2002;29(12):2577–82.PubMedGoogle Scholar
  201. 201.
    Tinazzi I, Adami S, Zanolin EM, Caimmi C, Confente S, Girolomoni G, et al. The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis. Rheumatology (Oxford). 2012;51(11):2058–63.CrossRefGoogle Scholar
  202. 202.
    Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012;71(3):319–26.PubMedCrossRefGoogle Scholar
  203. 203.
    Ash Z, Aydin SZ, Tan AL, McGonagle D. Arthritis. In: Rigopoulos D, Tosti A, editors. Nail psoriasis from A to Z. Switzerland: Springer International Publishing; 2014. p. 34–41.Google Scholar
  204. 204.
    Piraccini BM, Starace M. Nail psoriasis in special populations: children, pregnant, elderly. In: Rigopoulos D, Tosti A, editors. Nail psoriasis from A to Z. Switzerland: Springer International Publishing; 2014. p. 132–46.Google Scholar
  205. 205.
    Piraccini BM, Triantafyllopoulou I, Prevezas C, Starace M, Neri I, Patrizi A, Caserini M, Palmieri R, Rigopoulos D. Nail psoriasis in children: common or uncommon? Results from a 10-year double-center study. Skin Appendage Disord. 2015;1:43–8.PubMedPubMedCentralCrossRefGoogle Scholar
  206. 206.
    Iorizzo M, Vincenzi C, Smith FJ, Wilson NJ, Tosti A. Pachyonychia congenita type I presenting with subtle nail changes. Pediatr Dermatol. 2009;26:492–3.PubMedCrossRefGoogle Scholar
  207. 207.
    Tosti A, Peluso AM, Zucchelli V. Clinical features and long-term follow-up of 20 cases of parakeratosis pustulosa. Pediatr Dermatol. 1998;15:259–63.PubMedCrossRefGoogle Scholar
  208. 208.
    Gordon KA, Vega JM, Tosti A. Trachyonychia: a comprehensive review. Indian J Dermatol Venereol Leprol. 2011;77:640–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.National and Kapodistrian University of Athens, Medical school, 2nd Department of Dermatology, Attikon HospitalAthensGreece

Personalised recommendations